FindTrial
Sign In

MRTX1719

DRUG5 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb, M.D. Anderson Cancer Center

Conditions

Advanced CancerAdvanced Solid TumorAdvanced or Metastatic Non-small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsMesotheliomaNon Small Cell Lung CancerPancreatic AdenocarcinomaSolid Tumor

Phase 1

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingNCT05245500
Bristol-Myers SquibbAdvanced Solid Tumor, Malignant Peripheral Nerve Sheath Tumors, Mesothelioma +3
Start: 2022-06-09End: 2027-12-10Target: 336Updated: 2026-09-02
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RecruitingNCT07382544
M.D. Anderson Cancer CenterAdvanced Cancer, Solid Tumor
Start: 2026-02-12End: 2032-01-31Target: 36Updated: 2026-08-12

Phase 2

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies
RecruitingCTIS2024-519814-29-00
Bristol-Myers Squibb Services Unlimited CompanyAdvanced or Metastatic Non-small Cell Lung Cancer
Start: 2025-09-12Target: 74Updated: 2026-01-26
A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion
RecruitingCTIS2025-521511-40-00
Bristol-Myers Squibb Services Unlimited Companymetastatic non-small cell lung cancer
Start: 2025-11-18Target: 191Updated: 2026-01-21
A randomized, phase 2/3 study comparing BMS-986504 in combination with Nab-paclitaxel and Gemcitabine versus placebo in combination with Nab-paclitaxel and Gemcitabine in participants with untreated metastatic pancreatic ductal adenocarcinoma harboring homozygous MTAP deletion
RecruitingCTIS2025-522598-12-00
Bristol-Myers Squibb Services Unlimited CompanyUntreated Metastatic Pancreatic Ductal Adenocarcinoma
Start: 2025-12-17Target: 162Updated: 2026-01-12

Related Papers

BMS-986504 in patients (pts) with advanced solid tumors with homozygous <i>MTAP</i> deletion ( <i>MTAP</i> -del): Exploratory pharmacodynamic (PD) and biomarker analyses from CA240-0007.
Journal of Clinical Oncology2026-05-27
BMS-986504 in patients (pts) with advanced solid tumors with homozygous <i>MTAP</i> deletion ( <i>MTAP</i> -del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007.
Journal of Clinical Oncology2025-05-282 citations
Abstract 4536: MTAP loss alters the epigenetic landscape and demonstrates superior therapeutic sensitivity to concomitant PRMT5 and PARP inhibition in cholangiocarcinoma
Cancer Research2024-03-221 citations
Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers
Cancer Research2023-04-041 citations